Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00442052 · ClinicalTrials.gov registry record · Phase 1
To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin
A Phase 1 study, sponsored by POZEN.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00442052 is a Phase 1 study that has completed, run by POZEN. The registered enrollment target is 80 participants.
The verdict
NCT00442052, a Phase 1 study, has completed, sponsored by POZEN.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
Primary: To compare the gastroprotective effects of a once-daily dose of PA 325 combination tablet combining 325 mg pH sensitive aspirin and 20 mg immediate release omeprazole versus a once-daily dose of 325 mg enteric coated aspirin utilizing Lanza scores from endoscopy findings in normal healthy volunteers.
Interventions
- DRUG aspirin
- DRUG omeprazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00442052
The ClinicalTrials.gov registry entry for NCT00442052 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is POZEN, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which aspirin is the first listed.
NCT00442052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00442052 about?
NCT00442052 is a clinical study titled "To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin". Primary: To compare the gastroprotective effects of a once-daily dose of PA 325 combination tablet combining 325 mg pH sensitive aspirin and 20 mg immediate release omeprazole versus a once-daily dose of 325 mg enteric coated aspirin utilizing Lanza scores from endoscopy findings in normal healthy v...
What is the current status of trial NCT00442052?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2006-11. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00442052?
The interventions under investigation include: aspirin (DRUG), omeprazole (DRUG).
Who is sponsoring clinical trial NCT00442052?
This trial is sponsored by POZEN, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.